CSS
CBAY

Cubist Systematic Strategies’s Cymabay Therapeutics CBAY Stock Holding History

Cubist Systematic Strategies’s Portfolio CBAY Stock Details CBAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-62,516
Closed -$932K – 4232
2023
Q3 		$932K Buy
62,516
+10,771
+21% +$143K 0.01% 1925
2023
Q2 		$567K Sell
51,745
-479,636
-90% -$4.47M ﹤0.01% 2314
2023
Q1 		$4.63M Buy
531,381
+478,052
+896% +$3.83M 0.03% 991
2022
Q4 		$334K Sell
53,329
-112,916
-68% -$429K ﹤0.01% 3288
2022
Q3 		$582K Buy
166,245
+114,911
+224% +$413K ﹤0.01% 3044
2022
Q2 		$151K Buy
51,334
+17,654
+52% +$42.2K ﹤0.01% 3818
2022
Q1 		$105K Buy
33,680
+9,189
+38% +$28.9K ﹤0.01% 3230
2021
Q4 		$83K Buy
24,491
+5,778
+31% +$21.9K ﹤0.01% 3237
2021
Q3 		$68K Sell
18,713
-44,987
-71% -$177K ﹤0.01% 2799
2021
Q2 		$278K Sell
63,700
-87,740
-58% -$389K ﹤0.01% 2383
2021
Q1 		$688K Buy
151,440
+73,861
+95% +$398K 0.01% 1776
2020
Q4 		$445K Buy
77,579
+20,613
+36% +$156K 0.01% 1833
2020
Q3 		$412K Buy
56,966
+41,130
+260% +$220K 0.01% 1856
2020
Q2 		$55K Buy
15,836
+2,577
+19% +$7.44K ﹤0.01% 2264
2020
Q1 		$20K Sell
13,259
-7,762
-37% -$13K ﹤0.01% 2065
2019
Q4 		$41K Sell
21,021
-14,075
-40% -$52.9K ﹤0.01% 2294
2019
Q3 		$180K Buy
35,096
+14,001
+66% +$84.8K ﹤0.01% 1814
2019
Q2 		$151K Buy
+21,095
New +$239K ﹤0.01% 2154
2019
Q1 		– Sell
-26,897
Closed -$212K – 2460
2018
Q4 		$212K Buy
26,897
+20,099
+296% +$191K 0.01% 1495
2018
Q3 		$75K Sell
6,798
-2,105
-24% -$26.1K ﹤0.01% 1648
2018
Q2 		$119K Sell
8,903
-14,866
-63% -$186K 0.01% 1488
2018
Q1 		$309K Buy
+23,769
New +$295K 0.02% 1126

Other funds holding CBAY

ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Cubist Systematic Strategies's CBAY Position: Q4 2023 in Review

Cubist Systematic Strategies sold out of Cymabay Therapeutics (CBAY) in Q4 2023, closing a stake of 62,516 shares — an estimated $932K sold.

Cubist Systematic Strategies first reported a position in CBAY in Q1 2018 and held it in 22 quarters. The position peaked at $4.63M in Q1 2023. 200 funds tracked by Wall St. Rank hold CBAY as of Q4 2023.

  • Cubist Systematic Strategies reported no remaining Cymabay Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Cubist Systematic Strategies sold 62,516 Cymabay Therapeutics shares in Q4 2023, an estimated $932K.
  • Cubist Systematic Strategies first reported a position in Cymabay Therapeutics in Q1 2018 and held it in 22 quarters.
  • Cubist Systematic Strategies's Cymabay Therapeutics position peaked at $4.63M in Q1 2023.
  • 200 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q4 2023.

Based on Cubist Systematic Strategies's 13F filing for Q4 2023, filed 14 Feb 2024.